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Abstract
Recent findings indicate that tumor-associated macrophages
are important drivers of tumor angiogenesis. Here, we review
the essential role played by Tie2-expressing monocytes (TEM)
in this phenomenon. TEMs are present in human blood
and tumors and their elimination in various tumor models
suppresses tumor angiogenesis. A ligand for Tie2, angiopoie-
tin-2 (Ang-2), is produced by angiogenic tumor vessels and
is a chemoattractant for TEMs. Hypoxia up-regulates Tie2
expression on TEMs and, together with Ang-2, down-regulates
their antitumor functions. Learning more about the regulation
of TEMs by the tumor microenvironment may yield new
strategies to ablate the tumor vasculature. [Cancer Res
2007;67(18):8429–32]
Bone Marrow–Derived Cells Regulate Tumor
Angiogenesis
Tumor angiogenesis—the generation of a tumor-associated
vascular system from host-derived, preexisting blood vessels—
occurs in response to the increasing demand for nutrients and
oxygen experienced by proliferating tumor cells. The angiogenic
process involves the activation, proliferation, and migration of
endothelial cells toward angiogenic stimuli produced by the tumor.
Once a primitive endothelial cell network is formed, the
recruitment of perivascular cells may enable stabilization of the
nascent vessels, functional lumen formation, and blood flow (1, 2).
It has recently emerged that a close interplay between cells of the
innate immune system and the developing vascular network takes
place during tumor angiogenesis (3). Innate immune cells such as
macrophages, granulocytes, and dendritic cells are prominent
components of both premalignant and malignant tissues and
contribute to tumor development by producing several factors that
directly or indirectly promote tumor angiogenesis. As early as in
1971, Folkman (4) postulated that inhibition of tumor angiogenesis
would be an effective strategy to treat human cancer. The
recognition of the critical interactions between immune cells and
tumor angiogenesis has led to the suggestion that targeting tumor-
infiltrating immune cells may represent a valuable antiangiogenic
strategy for cancer treatment (5).
One particular tumor-infiltrating, innate effector, the macro-
phage, has been shown to play a critical role in tumor development.
Monocytes are recruited from the bloodstream into tumors and, as
they extravasate across the tumor vasculature, begin to differen-
tiate into macrophages (6). Several studies have now shown that
these tumor-associated macrophages (TAM) promote both tumor
angiogenesis and metastasis (7). For example, when Lin et al. (8)
crossed MMTV-PyMT mice (which spontaneously develop mam-
mary tumors) with op/op mice, which lack a functional CSF-1 gene
(a crucial growth factor for macrophages and their precursors), the
tumors that grew in these macrophage-depleted mice showed a
slower rate of progression to malignancy and formed fewer
pulmonary metastases than those in CSF-1 wild-type mice.
Moreover, these authors recently showed that TAMs contribute
to the ‘‘angiogenic switch’’ that occurs when hyperplastic lesions
develop into early-stage carcinomas in MMTV-PyMT mice (9).
Most recently, an elegant study by Condeelis’ group has used
multiphoton imaging to visualize the cooperation between TAMs
and tumor cells during the process of tumor cell intravasation
and metastasis (10). These data are consistent with clinical find-
ings that high numbers of TAMs often correlate with increased
tumor vascularization and/or lymph node involvement in human
tumors (11).
TAM involvement in tumor angiogenesis is mediated, at least
in part, by their release of a wide array of proangiogenic factors
and enzymes, including vascular endothelial growth factor-A
(VEGF-A) and matrix metalloproteinase-9 (MMP-9). For example,
TAMs are an important source of VEGF-A in mouse mammary
(9) and human breast (12) tumors. Moreover, Coussens et al. (13)
used a transgenic mouse model of spontaneous skin tumorigen-
esis (K14-HPV) to show the essential role of MMP-9 production
by tumor-associated stromal cells, such as TAMs, in tumor
progression. It therefore came as no surprise that ablation of
TAMs using a DNA vaccine approach in various murine tumor
models resulted in marked reduction in tumor VEGF and MMP-
9 levels and the suppression of tumor angiogenesis, growth, and
metastasis (14).
One subset of monocytes has recently been shown to have
a particularly important role in tumor angiogenesis—those
expressing Tie2, an angiopoietin receptor thought previously to
be restricted mainly to endothelial cells and hematopoietic stem
cells (15, 16). The selective elimination of these Tie2-expressing
monocytes (TEM) by means of a suicide gene dramatically
impaired angiogenesis in mouse tumors and induced substantial
tumor regression (15, 16). The presence and phenotype of these
TEMs have now been defined in human blood and tumors
(15, 17, 18), and their role in tumor angiogenesis investigated
using cell transplantation assays. Furthermore, the pronounced
effects on TEMs of factors present in the tumor microenviron-
ment, such as hypoxia and angiopoietin-2 (Ang-2), have also now
been described (17, 18). These studies are outlined in greater
detail below.
Requests for reprints: Claire E. Lewis, Tumor Targeting Group, Academic Unit of
Pathology, The Sir Henry Wellcome Laboratories for Medical Research, University of
Sheffield Medical School, Sheffield S10 2RX, United Kingdom. Phone: 44-114-271-2903;
Fax: 44-114-271-2903; E-mail: claire.lewis@sheffield.ac.uk.
I2007 American Association for Cancer Research.
doi:10.1158/0008-5472.CAN-07-1684
www.aacrjournals.org 8429 Cancer Res 2007; 67: (18). September 15, 2007
Review
 American Association for Cancer Research Copyright © 2007 
 on June 12, 2012cancerres.aacrjournals.orgDownloaded from 
DOI:10.1158/0008-5472.CAN-07-1684
Identification of TEMs
Studies by De Palma et al. (15, 16) have identified TEMs in
several mouse tumor models, including s.c. tumors, human glio-
blastoma grown in the mouse brain, and spontaneous pancreatic
tumors developing in RIP1-Tag2 transgenic mice. In these, TEMs
were found to constitute a small subpopulation of the total tumor-
infiltrating, CD11b+ myeloid cells that could be distinguished from
the majority of TAMs by their surface marker profile (Tie2+Sca-
1+CD11b+), their preferential localization to areas of angiogenesis,
and their marked proangiogenic activity (15). These studies have
now been extended to show the existence of TEMs in a variety of
human tumors where they represented a small subset of tumor-
infiltrating leukocytes found largely in perivascular and avascular,
viable areas of human tumors. These cells were largely missing in
nonneoplastic tissues adjacent to tumors (17).
In addition to tumors, TEMs can be detected at low frequency in
the peripheral blood of both mice and humans (15, 17, 18).
Whereas only 1% to 2% of total leukocytes are Tie2+, a substantial
fraction (f20%) of circulating monocytes express Tie2 (17, 18). In
mice, the circulating Tie2+CD45+ hematopoietic cells are mostly
CD11b+Gr-1low/neg (15), whereas in humans they express CD14,
CD16, and CD11c (17, 18). The surface marker profile of mouse and
human TEMs is similar to that of the so-called ‘‘resident
monocytes,’’ a monocyte population distinct from the classic
inflammatory monocytes and thought to comprise precursors of
tissue macrophages (19). Previous studies have reported that a
subset of monocytes has the ability to differentiate into endothelial
cells on an appropriate stimulus and expresses some endothelial
cell markers, including Tie2 (20). However, we found that the vast
majority of the circulating Tie2+ cells lacked the expression of the
endothelial cell/endothelial cell precursor markers VEGFR-2,
AC133, CD146 (17), and CD34 (18), whereas they expressed pure
hematopoietic markers, such as CD45. Although a certain degree of
phenotypical and functional heterogeneity may exist among
circulating Tie2+ cells, these data indicate that the prominent
fraction of peripheral blood Tie2+ cells are bona fide monocytes.
Interestingly, circulating human TEMs do not express CCR2
(17), the receptor for CCL2 [also known as monocyte chemo-
attractant protein-1 (MCP-1)], a chemokine that regulates the
recruitment of monocytes to inflamed tissues and tumors.
Although the recruitment of TEMs to inflamed tissues has yet to
be investigated, it is tempting to speculate on the non-MCP-1
circuits that may govern the recruitment of TEMs to tumors.
TEMs may be attracted to tumors in a CCR2-independent manner
by signals produced by the tumor cells or stromal components of
the tumor, such as the blood vessels themselves. For example, as
discussed below, Ang-2, a Tie2 ligand up-regulated by tumors,
could play a role in this (17, 18).
Role of TEMs in Tumor Angiogenesis: Insights from
Mouse Tumor Models
TEMs have been shown to promote tumor angiogenesis in
various murine tumor models (15, 16). For example, murine TEMs
isolated by cell sorting from the peripheral blood and injected with
Matrigel s.c. in mice were more angiogenic than their Tie2-negative
counterparts. Moreover, when TEMs were isolated from murine
mammary tumors and injected with tumor cells s.c. in mice, the
early-stage tumors that developed from the injected cells were
significantly more vascularized than the tumors originating from
Figure 1. TEM recruitment to tumors. A, a human glioblastoma orthotopically injected in the mouse brain shows several TEMs (labeled by green fluorescent
protein, green ) associated with the tumor blood vessels (red , stained by an anti-CD31 monoclonal antibody). B, a human gastric adenocarcinoma stained with an
anti-Tie2 monoclonal antibody. Note the Tie2+ blood vessels and the presence of scattered Tie2+ mononuclear cells (TEMs, arrows ) in the stroma. Section was
counterstained by H&E. C, a human colon carcinoma stained with a fluorescent anti-Tie2 monoclonal antibody (red) shows Tie2+ blood vessels and scattered
Tie2+CD14+ TEMs (arrows ). Green, CD14+ monocytes were stained with a FITC-conjugated anti-CD14 monoclonal antibody. Double-positive cells (i.e., TEMs) appear
yellow . Bar, 50 Am.
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tumor cells alone or tumor cells coinjected with CD11b+Tie2neg
cells. Together, these data indicate that both circulating and tumor-
infiltrating TEMs have marked proangiogenic activity and suggest
that circulating TEMs might represent the precursors of the tumor
TEM population. Similar to murine cells, human TEMs also have
such proangiogenic activity (17). Indeed, Tie2+CD14+ cells isolated
from human peripheral blood by cell sorting, and coinjected with
human glioma cells s.c. in nude mice, markedly promoted tumor
vascularization, whereas CD14+Tie2neg monocytes failed to show
such activity (17).
To investigate the importance of TEMs in tumor angiogenesis,
transgenic mice were generated that express the conditionally toxic
gene thymidine kinase (tk) under the control of the murine Tie2
promoter/enhancer (Tie2-tk transgenic mice; ref. 15). In this mouse
model, proliferating Tie2-expressing cells can be selectively killed
by administration of the prodrug ganciclovir (GCV). Hematopoietic
progenitors cells from these Tie2-tk transgenic mice were trans-
planted into wild-type mice and, a few weeks later, inoculated with
either s.c. mammary tumors or orthotopic human gliomas. When
GCV was given to eliminate TEMs during the early stages of tumor
growth, tumors in GCV-treated mice were significantly smaller and
less vascularized than those of untreated mice, indicating that TEM
depletion was sufficient to inhibit tumor angiogenesis and growth
(15). One interesting finding was that TEM elimination did not
affect the overall number of TAMs, making it unlikely that TEMs
are simply precursors for TAMs or tissue macrophages in general.
Rather, it seems from these studies that TEMs represent a distinct
monocyte subset with inherent proangiogenic activity. Interesting-
ly, when GCV treatment was halted, s.c. mammary tumors
remained dormant for more than 2 weeks before resuming their
growth, suggesting that reconstitution of the TEM pool was
required before the tumors could switch angiogenesis back on and
resume their growth (15).
In addition to TEMs, other studies reported proangiogenic
activity of selected myeloid cell subsets in mouse tumors, including
VEGFR-1+CD11b+ hematopoietic progenitors, Gr-1+CD11b+ mye-
loid suppressor cells, and CD11c+MHC-II+ dendritic cell precursors
(3). Because many cell surface markers are broadly expressed
among myeloid cells, it is difficult to establish whether these
proangiogenic cells represent distinct hematopoietic populations,
rather than overlapping myeloid cell subsets, possibly comprising
the TEMs.
Because some TEMs preferentially localize to the vicinity of
tumor blood vessels in viable tumor areas (17), it can be envisaged
that they may provide paracrine support to nascent blood vessels
in these areas during the angiogenic process. In human glioma
xenografts, for instance, perivascular TEMs produce high levels of
the proangiogenic factor basic fibroblast growth factor (15). As
mentioned previously, other studies have suggested that the
proangiogenic activity of myeloid cells in tumors involves the
production of growth factors and matrix-remodeling proteins that
stimulate the angiogenic process in a paracrine manner (3). In
addition to these functions, TEMs could function as pathfinders for
activated endothelial cells or form provisional endothelium-like
structures for blood vessel formation.
Regulation of TEMs by the Tumor Microenvironment
In two recent studies (17, 18), Ang-2 has been shown to stimulate
migration of Tie2+ monocytes in vitro and to elicit this effect, at
least in part, via activation of Tie2 (17, 18). As Ang-2 is up-regulated
by tumor blood vessels (21), it may recruit TEMs into tumors by
attracting them toward the tumor vasculature. This scenario might
help to explain why TEMs are seen in clusters around angiogenic
vessels in some tumor models (15).
Lewis and her colleagues have shown that hypoxia up-regulates
Tie2 expression on human TEMs (18). Moreover, Naldini’s group
has shown that TEMs isolated from human tumors express Tie2 to
a higher extent than circulating TEMs (17). Together, these findings
suggest that hypoxia in the tumor microenvironment may up-
regulate Tie2 expression by TEMs, making them more responsive
to Ang-2 in hypoxic (i.e., highly angiogenic) tumor areas. Lewis’s
group showed that Ang-2 also modulates cytokine secretion by
TEMs. For example, it inhibits their release of tumor necrosis
factor-a (TNF-a), an interesting finding given that elevated levels
of TNF-a promote apoptosis of both tumor and endothelial cells
(22). The down-regulation of TNF-a by TEMs near Ang-2+ tumor
blood vessels may thus enhance tumor and endothelial cell
survival, thereby promoting metastasis and angiogenesis. Further-
more, in the presence of hypoxia, Ang-2 inhibits the expression of
the antiangiogenic cytokine interleukin-12 by TEMs (18), thereby
highlighting an important mechanism by which the tumor
microenvironment may down-regulate the antiangiogenic activities
of tumor-infiltrating macrophages. It remains to be investigated
whether hypoxia, Ang-2, and/or other Tie2 ligands also play a role
in regulating the activity of TEMs in tumors.
Concluding Remarks
The studies outlined above have unearthed the essential role
played by a small subset of tumor-infiltrating monocytes, those
that express Tie2, in regulating tumor angiogenesis. They may lead
to several new therapeutic approaches in anticancer treatment.
From the data discussed here, it follows that conventional
antiangiogenic therapy may be improved by drugs that concom-
itantly target this subset of proangiogenic monocytes. Assessing the
specific contribution of TEMs to human neoplastic disease,
together with the identification of selective targets for these cells,
may herald the design of new anticancer therapies. Monocytes/
macrophages are genetically stable cells that are less likely to
develop drug resistance than cancer cells, so drugs that inhibit
selected macrophage functions should hold promise for effective
anticancer therapies. The challenge now, however, is to understand
which targets could safely and effectively distinguish TEMs from
other effector cells in the body that regulate immune functions and
tissue homeostasis. Furthermore, it will be important to determine
whether TEM inhibition would affect physiologic processes. Given
their tumor-homing ability and selectivity, TEMs may be used as
surrogate markers to monitor angiogenesis in vivo or as gene
delivery vehicles to restrict antiangiogenic or antitumor gene
expression to the tumor site (16).
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